Company intelligence / Profile preview

Serono Laboratories

Geneva, Switzerland

Ownership: Private
Employees: ~5000
Development stage: Other

Overview

Serono was a premier Swiss biotechnology company that became a global leader in the fields of reproductive health and neurology. The company was renowned for its expertise in recombinant protein manufacturing, producing essential therapies for infertility, growth hormone deficiency, and multiple sclerosis. In 2007, Serono was acquired by Merck KGaA for approximately $13.5 billion, leading to the formation of Merck Serono (operating as EMD Serono in North America). At the time of its acquisition, it was the largest biotechnology company in Europe and a pioneer in mammalian cell culture technology.

Therapeutic areas: EndocrinologyNeurologyWomen's HealthInfectious Diseases
Modalities: Recombinant proteinHormoneMonoclonal antibody
Industry: Biotech

Partnerships

Pfizer

Beyond the preview

Go deeper on Serono Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Serono Laboratories.

Explore the full profile